

THANK YOU TO OUR SPONSORS!

Session Sponsor



Discovery Sponsor



Supporting Sponsors



GRAND CHALLENGES IN PARKINSON'S DISEASE

MODIFYING PROGRESSION –
FROM MOLECULES TO TRIALS

September 28–29, 2022



grandchallengesinpd.org

Wednesday, September 28, 2022

- 8:00 a.m. Welcome
Peter A. Jones, Ph.D., D.Sc. (hon) —
Van Andel Institute
- 8:05 a.m. Introduction of Keynote Speaker
Patrik Brundin, M.D., Ph.D. — Roche
- 8:10 a.m. Jay Van Andel Award for Outstanding
Achievement in Parkinson's Disease
Research Lecture
Anthony E. Lang, O.C., M.D., FRCPC, FAAN,
FCAHS, FRSC — University of Toronto
*Disease modification in Parkinson's disease:
Targets and challenges*
- 9:10 a.m. Discussion
- 9:25 a.m. Break

SESSION 1: MITOCHONDRIAL FUNCTION IN PD

**Session Chair: Randy Schekman, Ph.D. —
University of California, Berkeley**

- 9:40 a.m. J. Timothy Greenamyre, M.D., Ph.D. —
Pittsburgh Institute for Neurodegenerative
Diseases, University of Pittsburgh
*Parkinson's gene-environment interactions
at the mitochondrion*
- 10:10 a.m. Oliver Bandmann, M.D., Ph.D. — Sheffield
Institute for Translational Neuroscience
*The neuroprotective potential of
ursodeoxycholic acid (UDCA)*(VIRTUAL)
- 10:40 a.m. Nandakumar Narayanan, M.D., Ph.D. —
University of Iowa Carver College
of Medicine
*Glycolysis-enhancing drugs and neurodegeneration
in Parkinson's disease* (VIRTUAL)
- 11:10 a.m. Abstract Selected Talk
Jennifer A. Johnson, Ph.D. — NYSNOBio
*Changing the course of disease progression
with Parkin therapeutics: The master
regulator of mitochondria, autophagy
and inflammation*
- 11:25 a.m. Discussion
- 11:40 a.m. Lunch

SESSION 2: GLP-1 AGONIST

**Session Chair: Richard Wyse, Ph.D. —
Cure Parkinson's**

- 1:00 p.m. Dilan Athauda, MRCP, B.Sc., Ph.D. —
University of College London
*The GLP-1 receptor as a target in Parkinson's
disease*
- 1:30 p.m. Wassilios Meissner, M.D., Ph.D., FEAN —
University Hospital Bordeaux
*Clinical trial of lixisenatide in patients with
early PD* (VIRTUAL)
- 2:00 p.m. Michele Tagliati, M.D., FAAN — Cedars-Sinai
Medical Center
*A phase II, randomized, double-blinded,
placebo-controlled trial of liraglutide in
Parkinson's disease*
- 2:30 p.m. Discussion
- 2:45 p.m. Break
- SESSION 3: C-ABL INHIBITION**
**Session Chair: M. Judith Peterschmitt,
M.D., MMSc — Sanofi**
- 3:00 p.m. Milton Werner, Ph.D. — Inhibikase
Therapeutics, Inc.
*Clinical studies of a potential disease-
modifying agent for Parkinson's disease:
lkt-148009*
- 3:30 p.m. Tanya Simuni, M.D., FAAN — Northwestern
University Feinberg School of Medicine
*Clinical trials of c-Abl inhibition in
Parkinson's* (VIRTUAL)
- 4:00 p.m. Philippe Damier, M.D., Ph.D., FEAN —
University of Nantes
*Radotinib to slow down Parkinson disease
neurodegeneration: CAp preliminary results
of a phase IIa study*
- 4:30 p.m. Abstract Selected Talk
Kaitlyn Westra, B.S. — Van Andel Institute
*Exploring transcriptional differences and
the role of cellular senescence in cortex
tissue of Parkinson's disease patients by
single-nuclei RNAseq*

- 4:45 p.m. Discussion
- 5:00 p.m. Poster Session and Dinner
(Dinner tickets must have been purchased
during registration)

Thursday, September 29, 2022

SESSION 4: ALPHA-SYNUCLEIN

**Session Chair: Michael Henderson, Ph.D.
— Van Andel Institute**

- 8:00 a.m. Tiago Outeiro, Ph.D. — University Medical
Center Goettingen
*Glycation: A biomarker and target for
therapeutic intervention in Parkinson's
disease*
- 8:30 a.m. Denise Barbut, M.D., FRCP — Enterin, Inc.
*Targeting alpha-synuclein in the enteric
neuron to treat Parkinson's disease*
- 9:00 a.m. Gunther Staffler, Ph.D. — AC Immune SA
*Towards a Parkinson's disease vaccine:
Targeting aggregated alpha synuclein species
using ACI-7104*
- 9:30 a.m. Abstract Selected Talk
Camille B Carroll, Ph.D. — University of
Plymouth
*Towards a multi-arm, multi-stage platform
trial of disease-modifying approaches in
Parkinson disease. The Edmond J Safra
ACT-PD Initiative.*
- 9:45 a.m. Discussion
- 10:00 a.m. Break

SESSION 5: NEUROINFLAMMATION

**Session Chair: Darren Moore, Ph.D. —
Van Andel Institute**

- 10:15 a.m. Ashley Harms, Ph.D. — The University of
Alabama at Birmingham
*Alpha-synuclein and the immune response
in PD*

- 10:45 a.m. David Standaert, M.D., Ph.D. — The
University of Alabama at Birmingham
*Neuroinflammation in human Parkinson's
disease*
- 11:15 a.m. Pete Thornton, Ph.D. — NodThera Inc.
*Brain penetrant NLRP3 inhibitors for the
treatment of Parkinson's disease*
- 11:45 a.m. Discussion
- 12:00 p.m. Lunch
- 1:00 p.m. *10 years of iLCT*
Chaired by Darren Moore, Ph.D. —
Van Andel Institute
- 1:30 p.m. Findings from Rallying to the Challenge
- 1:50 p.m. Tom Isaacs Award Presentation

SESSION 6: LYSOSOMAL TARGETS

**Session Chair: Ashley Harms, Ph.D. — The
University of Alabama at Birmingham**

- 2:15 p.m. Lena Burbulla, Ph.D. — Biomedical Center,
LMU Munich
*Convergence of mitochondrial and lysosomal
dysfunction in Parkinson's disease*
- 2:45 p.m. M. Judith Peterschmitt, M.D., MMSc — Sanofi
*GBA-Parkinson's disease: Lessons learned
from the MOVES-PD study and challenges
ahead*
- 3:15 p.m. Ravi Jagasia, Ph.D. — F. Hoffman-
La Roche AG
*Targeting neuronal β -glucocerebrosidase
deficiency with an enzyme-based Brain
Shuttle molecule*

- 3:45 p.m. Discussion
- 4:00 p.m. Closing Remarks